Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

8.110 +0.070 (+0.87%)
Streaming Delayed Price Updated: 10:01 AM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Preview: DiaMedica Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 17, 2025 ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics Upcoming Conference Participation
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024 ↗
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 ↗
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.